Patrick O’Donnell

501 total citations
14 papers, 122 citations indexed

About

Patrick O’Donnell is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Patrick O’Donnell has authored 14 papers receiving a total of 122 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Patrick O’Donnell's work include Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Patrick O’Donnell is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Cancer Genomics and Diagnostics (6 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Patrick O’Donnell collaborates with scholars based in United States, United Kingdom and Spain. Patrick O’Donnell's co-authors include Kenneth Emancipator, Raanan Berger, Joaquim Bellmunt, Elizabeth R. Plimack, J. Cheng, Kumudu Pathiraja, Rodolfo F. Perini, Marisa Dolled‐Filhart, Shilpa Gupta and Edward J. Gonzalez and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Patrick O’Donnell

14 papers receiving 119 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick O’Donnell United States 5 77 49 41 29 26 14 122
Brian Hunis United States 6 57 0.7× 41 0.8× 33 0.8× 24 0.8× 20 0.8× 28 111
Xu-Shan Sun France 7 124 1.6× 80 1.6× 36 0.9× 22 0.8× 36 1.4× 13 193
Mariaelena Casagrande Italy 8 91 1.2× 45 0.9× 37 0.9× 15 0.5× 15 0.6× 21 123
Effie Skrinos Australia 4 109 1.4× 55 1.1× 44 1.1× 21 0.7× 43 1.7× 8 151
Ina Valeria Zurlo Italy 6 105 1.4× 89 1.8× 42 1.0× 40 1.4× 36 1.4× 24 191
Juan Francisco Rodríguez-Moreno Spain 9 86 1.1× 71 1.4× 59 1.4× 50 1.7× 74 2.8× 37 192
David Dum Germany 6 55 0.7× 42 0.9× 24 0.6× 21 0.7× 31 1.2× 16 115
Jie Bin Liu United States 3 135 1.8× 83 1.7× 75 1.8× 13 0.4× 35 1.3× 3 184
Erik Asmus United States 6 100 1.3× 41 0.8× 17 0.4× 36 1.2× 39 1.5× 9 179
Akesu Sujie China 8 114 1.5× 90 1.8× 79 1.9× 11 0.4× 35 1.3× 17 180

Countries citing papers authored by Patrick O’Donnell

Since Specialization
Citations

This map shows the geographic impact of Patrick O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick O’Donnell more than expected).

Fields of papers citing papers by Patrick O’Donnell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick O’Donnell. The network helps show where Patrick O’Donnell may publish in the future.

Co-authorship network of co-authors of Patrick O’Donnell

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick O’Donnell. A scholar is included among the top collaborators of Patrick O’Donnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick O’Donnell. Patrick O’Donnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
3.
Castellano, Daniel, Petros Grivas, Elizabeth R. Plimack, et al.. (2018). Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052. European Urology Supplements. 17(2). e124–e125. 2 indexed citations
4.
Rosenberg, J., Arjun Vasant Balar, Patrick O’Donnell, et al.. (2018). EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy. European Urology Supplements. 17(2). e1152–e1152. 4 indexed citations
5.
Powles, Thomas, Joaquim Bellmunt, Daniel Castellano, et al.. (2017). Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052. European Urology Supplements. 16(3). e285–e286. 3 indexed citations
6.
O’Donnell, Patrick, et al.. (2016). A Real-time PCR Assay for the Detection of EGFR Mutations in FFPE Tissue and Plasma Samples of NSCLC Patients.. Journal of Clinical Oncology. 34(15_suppl). e23251–e23251. 1 indexed citations
7.
Rosenberg, J., Daniel P. Petrylak, Oyewale O. Abidoye, et al.. (2015). 21LBA Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): Results from a pivotal multicenter phase II study (IMvigor 210). European Journal of Cancer. 51. S720–S720. 10 indexed citations
8.
Plimack, Elizabeth R., Shilpa Gupta, Joaquim Bellmunt, et al.. (2014). A Phase 1B Study of Pembrolizumab (Pembro; Mk-3475) in Patients (Pts) with Advanced Urothelial Tract Cancer. Annals of Oncology. 25. v1–v1. 41 indexed citations
9.
10.
Sun, Jong‐Mu, Chris Karlovich, Wei Wen, et al.. (2013). Abstract B25: Serial monitoring of EGFR mutations in plasma and evaluation of EGFR mutation status in matched tissue and plasma from NSCLC patients treated with CO-1686.. Molecular Cancer Therapeutics. 12(11_Supplement). B25–B25. 4 indexed citations
11.
O’Donnell, Patrick, Julie Tsai, Mari Christensen, et al.. (2012). Abstract 1707: A real-time PCR assay for detecting EGFR mutations in formalin-fixed paraffin-embedded tissue (FFPET) specimens of non-small cell lung cancer (NSCLC). Cancer Research. 72(8_Supplement). 1707–1707. 2 indexed citations
12.
Benlloch, Susana, Miquel Tarón, María Luisa Botero, et al.. (2012). Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay.. Journal of Clinical Oncology. 30(15_suppl). 10596–10596. 2 indexed citations
13.
O’Donnell, Patrick, Andrew Artz, Samir D. Undevia, J. W. Hart, & Koen van Besien. (2008). Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoetic stem cell transplantation (alloHCT). Journal of Clinical Oncology. 26(15_suppl). 7042–7042. 4 indexed citations
14.
O’Donnell, Patrick. (2000). In Vivo Purging With Rituximab During Stem Cell Transplantation for Indolent Lymphoma. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian Hunis Breakdown of academic impact, for papers by Xu-Shan Sun Breakdown of academic impact, for papers by Mariaelena Casagrande Breakdown of academic impact, for papers by Effie Skrinos Breakdown of academic impact, for papers by Ina Valeria Zurlo Breakdown of academic impact, for papers by Juan Francisco Rodríguez-Moreno Breakdown of academic impact, for papers by David Dum Breakdown of academic impact, for papers by Jie Bin Liu Breakdown of academic impact, for papers by Erik Asmus Breakdown of academic impact, for papers by Akesu Sujie
Rankless by CCL
2026